3-氯-2-(氯甲基)吡啶盐酸盐 | 124425-87-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-氯-2-(氯甲基)吡啶盐酸盐
• 英文名称: 3-chloro-2-(chloromethyl)pyridine hydrochloride
• 英文别名: 3-chloro-2-(chloromethyl)pyridine;hydrochloride
• CAS: 124425-87-2
• 化学式: C₆H₅Cl₂N*ClH
• 分子量: 198.479
• InChiKey: WOWKPCRREBTZCL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  12.9
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2933399090
• 包装等级：
  II
• 危险类别：
  8
• 危险性防范说明：
  P501,P260,P270,P271,P264,P280,P362+P364,P303+P361+P353,P301+P330+P331,P301+P312+P330,P304+P340+P310,P305+P351+P338+P310,P405
• 危险品运输编号：
  3261
• 危险性描述：
  H302+H312+H332,H314

反应信息

• 作为反应物：
  描述：

  2-tert-butyl-6-chloro-9H-purine 、 3-氯-2-(氯甲基)吡啶盐酸盐 以to give the title compound (208 mg, 26%) as off-white solid的产率得到2-tert-butyl-6-chloro-9-((3-chloropyridin-2-yl)methyl)-9H-purine
  参考文献：
  名称：

  PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS

  摘要：

  本发明涉及一种式（I）的化合物，其中A和R1到R4的定义如说明书和权利要求所述。该式（I）的化合物可用作药物。

  公开号：

  US20160046631A1

文献信息

• Amine-Linked Flavonoids as Agents against Cutaneous Leishmaniasis
  作者：Chin-Fung Chan、Zhen Liu、Iris L. K. Wong、Xianliang Zhao、Zaofeng Yang、Jiale Zheng、Marianne M. Lee、Michael K. Chan、Tak Hang Chan、Larry M. C. Chow

  DOI：10.1128/aac.02165-20

  日期：2021.4.19

  We have designed, synthesized, and characterized a library of 38 novel flavonoid compounds linked with amines. Some of these amine-linked flavonoids have potent in vitro activity against parasites that cause cutaneous leishmaniasis, a tropical disease endemic in 80 countries worldwide.

  我们设计、合成并鉴定了一个由 38 种与胺相连的新型类黄酮化合物组成的化合物库。其中一些与胺相连的黄酮类化合物具有强效的 体外 对引起皮肤利什曼病（一种在全球 80 个国家流行的热带疾病）的寄生虫有很强的体外活性。
• Spiro-oxindole compounds and their use as therapeutic agents
  申请人：Xenon Pharmaceuticals Inc.

  公开号：US08263606B2

  公开（公告）日：2012-09-11

  This invention is directed to spiro-oxindole compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.

  本发明涉及螺环-氧吲哚化合物，包括其立体异构体、对映异构体、互变异构体或其混合物；或其药学上可接受的盐、溶剂化物或前药，用于治疗和/或预防钠通道介导的疾病或病状，如疼痛。
• SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS
  申请人：Chafeev Mikhail

  公开号：US20100137299A1

  公开（公告）日：2010-06-03

  This invention is directed to spiro-oxindole compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.

  本发明涉及螺环氧吲哚化合物，包括其立体异构体、对映异构体、互变异构体或其混合物；或其药学上可接受的盐、溶剂化合物或前药，用于治疗和/或预防钠通道介导的疾病或症状，例如疼痛。
• SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS
  申请人：Chafeev Mikhail

  公开号：US20120295897A1

  公开（公告）日：2012-11-22

  This invention is directed to spiro-oxindole compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.

  本发明涉及螺环氧吲哚化合物，包括立体异构体、对映体、互变异构体或其混合物；或其药学上可接受的盐、溶剂合物或前药，用于治疗和/或预防钠通道介导的疾病或病症，例如疼痛。
• Spiro-oxindole compounds and their uses as therapeutic agents
  申请人：Chafeev Mikhail

  公开号：US08415370B2

  公开（公告）日：2013-04-09

  This invention is directed to spiro-oxindole compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.

  这项发明涉及螺环氧吲哚化合物，包括其立体异构体、对映异构体、互变异构体或其混合物；或其药学上可接受的盐、溶剂化合物或前药，用于治疗和/或预防钠通道介导的疾病或病症，如疼痛。